What is it about?
Higher mortality among COVID-19 diabetic population was due to older age and higher glycemia at admission; while DPP4 inhibitors may be associated with a better outcome.
Featured Image
Read the Original
This page is a summary of: Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy, Diabetes Care, October 2020, American Diabetes Association,
DOI: 10.2337/dc20-1340.
You can read the full text:
Contributors
The following have contributed to this page
